$1.29 Billion is the total value of Avoro Capital Advisors LLC's 45 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KITE | Sell | KITE PHARMA INC | $89,363,000 | +6.8% | 496,983 | -38.4% | 6.93% | -34.4% |
| TSRO | Sell | TESARO INC | $25,186,000 | -55.0% | 195,092 | -51.3% | 1.95% | -72.4% |
| AVEO | Sell | AVEO PHARMACEUTICALS INC | $17,543,000 | +19.1% | 4,806,249 | -27.5% | 1.36% | -26.8% |
| AGEN | Sell | AGENUS INC | $10,847,000 | -12.9% | 2,459,554 | -22.7% | 0.84% | -46.5% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS INC | $9,319,000 | -14.2% | 1,778,525 | -9.0% | 0.72% | -47.3% |
| CLLS | Sell | CELLECTIS S Asponsored ads | $2,227,000 | +0.7% | 78,289 | -8.6% | 0.17% | -38.0% |
| MDCO | Exit | MEDICINES COcall | $0 | – | -200,000 | -100.0% | -0.01% | – |
| SRNE | Exit | SORRENTO THERAPEUTICS INC | $0 | – | -416,230 | -100.0% | -0.10% | – |
| Exit | NEURODERM LTD | $0 | – | -44,516 | -100.0% | -0.17% | – | |
| Exit | SPDR S&P 500 ETFput | $0 | – | -250,000 | -100.0% | -0.18% | – | |
| AXGT | Exit | AXOVANT SCIENCES LTD | $0 | – | -82,087 | -100.0% | -0.24% | – |
| PTCT | Exit | PTC THERAPEUTICS | $0 | – | -120,000 | -100.0% | -0.28% | – |
| FBIO | Exit | FORTRESS BIOTECH INC | $0 | – | -603,657 | -100.0% | -0.36% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -50,000 | -100.0% | -0.47% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -800,000 | -100.0% | -0.89% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -219,500 | -100.0% | -1.28% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INC | $0 | – | -230,842 | -100.0% | -1.53% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -614,200 | -100.0% | -2.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.